Table 1.

The role of AR in BC subtypes.

Tumor subtype	AR role	Reference
ER+	Tumor-suppressor: associated with low aggressiveness and better outcome	Peters et al., 2009; Castellano et al., 2010; Vera-Badillo et al., 2014; Basile et al., 2017; Kim et al., 2017; Rangel et al., 2018a,b; Ricciardelli et al., 2018
TNBC	Tumor-suppressor: associated with low aggressiveness and progression, and better outcome Oncogenic: associated with aggressiveness and worse outcome	McNamara et al., 2014; Wang et al., 2016,Hu et al., 2011; McGhan et al., 2014
TNBC AR+/EGFR- TNBC AR+/EGFR+ TNBC AR-/EGFR- TNBC AR-/EGFR+	Associated with better prognosis Group with intermediate risk Associated with worse prognosis	Astvatsaturyan et al., 2018
MA ER-	ER mimic	Robinson et al., 2011; Severson et al., 2018
HER2-enriched	Proliferative	Naderi and Hughes-Davies, 2008; Ni et al., 2011; Chia et al., 2015; He et al., 2017; Daemen and Manning, 2018
Luminal A primary tumors	Favorable prognostic marker	Kraby et al., 2018